IWMF

International Waldenstrom's Macroglobulinemia Foundation

Publications

All publications
Sequential Treatment Escalation Improves Survival in Patients With Waldenstrom Macroglobulinemia

Sequential Treatment Escalation Improves Survival in Patients With...

2024

View
Bing-Neel Syndrome: A Rare Neurological Complication of Waldenström Macroglobulinaemia

Bing-Neel Syndrome: A Rare Neurological Complication of Waldenström...

2024

View
A Mystery in a Case: Unraveling the Complexity of Bing-Neel Syndrome

A Mystery in a Case: Unraveling the Complexity of Bing-Neel Syndrome

2024

View
Biomarker Analysis of the Aspen Study Comparing Zanubrutinib to Ibrutinib in Patients With Waldenström Macroglobulinemia

Biomarker Analysis of the Aspen Study Comparing Zanubrutinib to Ibrutinib in...

2024

View
A Phase Ii Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinaemia

A Phase Ii Study of Ibrutinib in Combination With Ixazomib in Patients With...

2024

View
Personalized Neoantigen Vaccines as Early Intervention in Untreated Patients With Lymphoplasmacytic Lymphoma: A Non- Randomized Phase 1 Trial

Personalized Neoantigen Vaccines as Early Intervention in Untreated Patients...

2024

View
The Landscape of Rare Genetic Variants in Familial Waldenström Macroglobulinemia

The Landscape of Rare Genetic Variants in Familial Waldenström Macroglobulinemia

2024

View
New Insights Into the Mechanisms Regulating Plasma Cell Survival and Longevity

New Insights Into the Mechanisms Regulating Plasma Cell Survival and Longevity

2024

View
Cardiovascular Events Reported in Patients With B-Cell Malignancies Treated With Zanubrutinib

Cardiovascular Events Reported in Patients With B-Cell Malignancies Treated...

2024

View
How We Use Genomics and BTK-Inhibitors in the Treatment of Waldenstrom Macroglobulinemia.

How We Use Genomics and BTK-Inhibitors in the Treatment of Waldenstrom...

2024

View